How to Get Testosterone Enanthate in Colorado

Colorado Telehealth Law and Testosterone Prescribing

Colorado permits licensed prescribers to evaluate, diagnose, and prescribe controlled substances via telehealth, including Schedule III medications like testosterone enanthate. The Ryan Haight Act requires at least one valid medical evaluation before a controlled substance prescription, and Colorado's telehealth framework satisfies this requirement through synchronous audio-video visits 1.

A prescriber licensed in Colorado (or holding a Colorado telehealth registration) can order labs, review results, and write a testosterone enanthate prescription without an in-person office visit. The Endocrine Society's 2018 clinical practice guideline recommends confirming hypogonadism with two separate morning total testosterone measurements below 300 ng/dL before initiating therapy 2. Telehealth platforms typically partner with national lab networks (Quest, Labcorp) that have draw sites across Colorado's Front Range and Western Slope.

Colorado does not impose a separate in-person requirement for ongoing TRT management. Follow-up labs at 3, 6, and 12 months can be ordered remotely and results reviewed during a video visit 3. This makes telehealth a practical option for patients in rural counties like San Juan, Mineral, or Hinsdale, where the nearest endocrinology office may be 100+ miles away.

Required Labs Before Starting Testosterone Enanthate

Two fasting morning blood draws form the diagnostic foundation. Total testosterone must fall below 300 ng/dL on both samples 2. Morning draws matter because testosterone follows a circadian rhythm, peaking between 7:00 and 10:00 AM and declining 20 to 25% by afternoon 4.

Beyond total testosterone, the American Urological Association (AUA) recommends a baseline panel that includes free testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, complete blood count (CBC), comprehensive metabolic panel, lipid panel, and PSA for men over 40 5. Hematocrit is particularly important. The T-Trials (N=790) demonstrated that testosterone treatment increased hematocrit by a mean of 3.2% over 12 months, with 3.5% of treated men exceeding 54% 6. Hematocrit above 54% triggers a dose reduction or temporary hold per the Endocrine Society guideline 2.

Most Colorado-based telehealth providers include lab work in their initial evaluation fee or support insurance-billed lab orders. Expect results within 48 to 72 hours from major reference labs.

Who Can Prescribe Testosterone Enanthate in Colorado

Colorado grants prescriptive authority for Schedule III controlled substances to multiple provider types. MDs and DOs with active Colorado medical licenses can prescribe independently. That's straightforward.

Nurse practitioners hold full practice authority in Colorado under CRS § 12-255-112, meaning they can prescribe testosterone enanthate without physician supervision after completing 1 to 000 hours of mentored prescribing 7. Physician assistants may prescribe controlled substances under a delegatory agreement with a supervising physician, as outlined in Colorado's Medical Practice Act 8.

The FDA-approved labeling for testosterone enanthate specifies its indication as replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism 9. Any qualifying prescriber must document the diagnosis to comply with DEA recordkeeping requirements for Schedule III substances.

Insurance Coverage and Colorado Medicaid

Colorado Medicaid does not cover testosterone enanthate for male hypogonadism as a standalone diagnosis. Coverage is restricted to specific endocrine conditions, and straightforward low testosterone without a qualifying comorbidity like type 2 diabetes will result in a denial 10.

Commercial insurers in Colorado (Anthem, Cigna, UnitedHealthcare, Kaiser Permanente of Colorado) generally cover testosterone enanthate with prior authorization. The prior authorization packet typically requires documentation of two low morning testosterone values, the clinical indication, and evidence that the patient has symptoms consistent with hypogonadism 11. The FDA's 2015 safety communication clarified that testosterone products carry labeling for classical hypogonadism only, which has tightened some payers' approval criteria 11.

For patients paying out of pocket, testosterone enanthate (200 mg/mL, 5 mL vial) from a commercial pharmacy costs $30, 80 per vial. Compounded formulations from 503A pharmacies may cost $40, 120 per month depending on concentration and volume.

503A Compounding Pharmacies in Colorado

Colorado licenses 503A compounding pharmacies through the Colorado State Board of Pharmacy under the authority of the federal Drug Quality and Security Act (2013) 12. These pharmacies can compound testosterone enanthate in customized concentrations (commonly 200 mg/mL or 250 mg/mL) based on a valid patient-specific prescription.

A 503A pharmacy compounds medications for individual patients in response to a prescription, not in bulk for distribution. This distinction separates them from 503B outsourcing facilities, which can produce larger quantities without patient-specific prescriptions 12. Colorado 503A pharmacies can ship within the state, and many telehealth TRT providers coordinate directly with these pharmacies to handle fulfillment.

When choosing a compounding pharmacy, verify that the facility holds a current Colorado Board of Pharmacy license. The pharmacy should use USP 797 and USP 800 standards for sterile compounding, which govern particulate contamination limits, beyond-use dating, and hazardous drug handling 13.

Dosing and Administration for Colorado Patients

The standard testosterone enanthate protocol is 100 to 200 mg administered intramuscularly once weekly, though some clinicians prefer twice-weekly dosing at half the total weekly dose to reduce peak-trough fluctuations 9. The Endocrine Society guideline recommends targeting a mid-normal serum testosterone of 450 to 600 ng/dL measured at trough (the day of or day before the next injection) 2.

Self-injection is the norm. Patients draw from a multi-dose vial using an 18-gauge needle and inject with a 25-gauge, 1-inch needle into the vastus lateralis or deltoid. Colorado does not restrict patient self-administration of injectable testosterone.

The T-Trials (NEJM 2016, N=790) demonstrated clinically meaningful benefits of testosterone gel (which shares the same active hormone) in men 65 and older with confirmed low testosterone: sexual function improved by 0.58 points on the PDQ (P<0.001), physical function showed modest gains, and mood scores improved significantly compared to placebo 6. While the T-Trials used transdermal gel rather than enanthate injections, the physiological endpoint (restoring serum testosterone to mid-normal range) is identical across formulations 14.

Monitoring and Follow-Up Requirements

The AUA guideline recommends follow-up labs at 3 months, 6 months, and then annually 5. Each follow-up panel should include total testosterone (drawn at trough), hematocrit, PSA (for men over 40), and a metabolic panel. Hematocrit monitoring is non-negotiable. A meta-analysis of 51 randomized trials (N=3,431) found that testosterone therapy increased the risk of erythrocytosis (hematocrit >54%) with a relative risk of 3.18 (95% CI 1.92, 5.26) 15.

Dr. Shalender Bhasin, principal investigator of the T-Trials, has stated: "Clinicians should not prescribe testosterone to men who have not had at least two morning total testosterone measurements confirming levels below 300 ng/dL" 2.

Estradiol monitoring is appropriate when patients report symptoms of aromatization (gynecomastia, water retention). The Endocrine Society does not mandate routine estradiol checks, but many TRT-focused clinicians include sensitive estradiol in follow-up panels 2. PSA velocity greater than 1.4 ng/mL per year warrants urology referral, per the AUA position statement 5.

Cardiovascular Safety Considerations

The TRAVERSE trial (NEJM 2023, N=5,246) was the first adequately powered randomized controlled trial to assess cardiovascular safety of testosterone in men aged 45, 80 with hypogonadism and established or high risk for cardiovascular disease. The primary endpoint (a composite of death from cardiovascular causes, nonfatal MI, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96; 95% CI 0.78, 1.17), meeting the prespecified noninferiority margin 16.

The FDA updated testosterone product labeling in 2015 to include warnings about potential cardiovascular risk 11. TRAVERSE data published eight years later provided reassurance, though the incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury was numerically higher in the testosterone arm 16. Colorado prescribers should discuss these findings during informed consent.

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, noted regarding TRAVERSE: "This trial should give clinicians more confidence that testosterone therapy does not increase the risk of major cardiovascular events in hypogonadal men" 16.

Transferring a Testosterone Enanthate Prescription to Colorado

Patients relocating to Colorado can transfer an existing testosterone enanthate prescription from another state. Colorado Board of Pharmacy regulations permit the transfer of Schedule III prescriptions between pharmacies as long as the original prescription has remaining refills 17. The receiving Colorado pharmacy contacts the originating pharmacy to verify the prescription details, remaining quantity, and prescriber information.

If the original prescription has no remaining refills, the patient needs a new prescription from a Colorado-licensed provider. Telehealth makes this transition efficient: recent lab work (within the past 6 months) from the prior state is typically accepted, avoiding duplicate blood draws. The new Colorado prescriber must still confirm the diagnosis meets the Endocrine Society criteria before reissuing 2.

Prior Authorization Documentation

When a Colorado commercial insurer requires prior authorization, the prescriber submits a clinical summary documenting the diagnosis code (ICD-10 E29.1 for testicular hypofunction), two qualifying morning testosterone levels, symptoms (fatigue, decreased libido, erectile dysfunction, loss of muscle mass), and confirmation that secondary causes have been excluded 18. MRI of the pituitary may be required if LH/FSH are inappropriately low, suggesting a central cause 2.

Turn-around time for PA decisions in Colorado ranges from 24 hours (for electronic submissions through CoverMyMeds or SureScripts) to 5, 7 business days for fax-based submissions. If denied, the prescriber can file a peer-to-peer appeal with the insurer's medical director. Denial rates for testosterone enanthate with complete documentation are low when both testosterone values and symptom documentation are clearly presented 19.

Timeline from Evaluation to First Injection

The typical process takes 10 to 14 days. Day 1 involves the initial telehealth consultation and lab order. Labs are drawn within 1 to 3 days at a local Quest or Labcorp site. Results return in 2, 3 business days. If testosterone is below 300 ng/dL, a second draw is ordered 2 to 4 weeks later per the Endocrine Society two-draw requirement 2. After the second confirmatory draw and result review, the prescription is sent to a pharmacy.

Pharmacy fulfillment from a 503A compounder takes 3, 7 business days including shipping. Commercial pharmacies (Walgreens, CVS, King Soopers) can fill same-day if the medication is in stock and no PA is required. Total elapsed time from first visit to first injection: 3 to 6 weeks when accounting for the two-draw requirement.